Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Clearmind Medicine: CMND-100 meets primary endpoint in Phase I/IIa study
Clearmind Medicine reports that the drug candidate CMND-100 met the primary endpoint for safety and tolerability in an FDA‑approved Phase I/IIa study for the treatment of alcohol use disorders. The third cohort showed a strong safety profile with no serious adverse events, even at higher doses, and the dose‑escalation phase confirmed good tolerability. The news boosted the share price (up about 15% to $1.43), and external analyses currently view the stock as trading below their estimated fair value, noting the company has more liquid assets than debt. » More on de.investing.com
Financials
| (EUR) | Apr 2026 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -11.85K | 12.05% |
| Net profit | -1.75M | 152.00% |
| EBITDA | -1.33M | 102.10% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €2.26M |
Number of shares | 1.49M |
52-week high/low | €452.27 - €1.23 |
| Dividends | No |
Beta | -1.25 |
P/E ratio | -0.15 |
PEG ratio | 0.00 |
P/B ratio | 0.05 |
P/S ratio | 0.00 |
Company profile
| Name | CLEARMIND MEDI.INC.O.N. |
| CEO | Adi Zuloff-Shani |
| Employees | 4 |
Discover assets
Shareholders of CLEARMIND MEDI.INC.O.N. also invest in the following assets
